Tumor and Organ Dose Estimates from 177 Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
J Nucl MedOct 1, 2026 (epub)
Zachary Ells, Catherine Meyer, Karam Masri et al.
✦ AI-curated · Sources linked
In 30 seconds
The RESIST-PC Phase 2 trial assessed dosimetry of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. A total of 48 patients were analyzed, receiving either 6.0 or 7.4 GBq per cycle. The study found no significant difference in organ or tumor absorbed doses between the two activity regimens, with mean absorbed doses to bone lesions being 1.90 ± 1.83 Gy/GBq and 1.64 ± 1.77 Gy/GBq, respectively.
Key findings
- Mean absorbed doses to kidneys, submandibular, parotid, and liver were 0.29 ± 0.11, 0.23 ± 0.18, 0.26 ± 0.15, and 0.11 ± 0.09 Gy/GBq, respectively.
- Mean absorbed dose to bone lesions was 1.90 ± 1.83 Gy/GBq for the 6.0-GBq group and 1.64 ± 1.77 Gy/GBq for the 7.4-GBq group.
- For lymph node lesions, mean absorbed doses were 5.61 ± 3.93 Gy/GBq for the 6.0-GBq group and 1.79 ± 1.96 Gy/GBq for the 7.4-GBq group.
- A significant inverse correlation was found between prostate-specific antigen response and tumor absorbed dose (ρ = -0.404, P = 0.006).
Why it matters
Understanding the absorbed doses from [177Lu]Lu-PSMA-617 therapy is crucial for optimizing treatment regimens in metastatic castration-resistant prostate cancer, potentially improving patient outcomes and minimizing adverse effects.